Core Points - Wuhan Heyuan Biotechnology Co., Ltd. (stock code: 688765) was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, opening at 88.00 yuan and closing at 91.10 yuan, a rise of 213.49% with a trading volume of 2.782 billion yuan and a turnover rate of 83.76% [1] - The company is an innovative biopharmaceutical enterprise with a leading global plant bioreactor technology platform [1] - The controlling shareholder and actual controller is Yang Daichang, who held 15.03% of the shares before the issuance and now holds 11.27% after the issuance, maintaining control over 21.93% of the voting rights [1] Financial Summary - The initial public offering (IPO) price was set at 29.06 yuan per share, with a total of 89.45 million shares issued, raising approximately 259.95 million yuan before expenses [2] - The net amount raised after deducting issuance costs was approximately 243.04 million yuan [2] - The total investment for the projects funded by the IPO includes 190.87 million yuan for the recombinant human albumin industrialization base, 79.37 million yuan for new drug research and development, and 10 million yuan for working capital, totaling 280.24 million yuan [4] Financial Performance - Over the past three and a half years, the company reported total revenue of 75.59 million yuan and a net loss of 564 million yuan [5] - Revenue for the years 2022 to 2025 (first half) was 13.40 million yuan, 24.26 million yuan, 25.22 million yuan, and 12.71 million yuan respectively, with net losses of 143.58 million yuan, 186.96 million yuan, 151.37 million yuan, and 81.63 million yuan [6][7] - The company has a high R&D expenditure relative to revenue, with R&D expenses accounting for 440.08% of revenue in the first half of 2025 [7]
禾元生物上市募26亿首日涨213% 近三年半共亏损5.6亿